Bots, editor, reviewer, Administrators
13,941
edits
WikiJournalClub:Usable articles: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS | * [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS | ||
* [[CAST I]] (1991): Antiarrhythmics post-MI | * [[CAST I]] (1991): Antiarrhythmics post-MI | ||
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention | |||
* [[COMMIT]] (2005): Metoprolol in acute MI | * [[COMMIT]] (2005): Metoprolol in acute MI | ||
* [[CURE]] (2001): Clopidogrel in UA/NSTEMI | * [[CURE]] (2001): Clopidogrel in UA/NSTEMI | ||
| Line 55: | Line 56: | ||
'''Cardiovascular Disease''' | '''Cardiovascular Disease''' | ||
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention | |||
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM | * [[Look AHEAD]] (2013): Weight loss and exercise in T2DM | ||
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM | * [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM | ||
| Line 69: | Line 71: | ||
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS | * [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS | ||
* [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD | * [[BARI 2D]] (2009): CABG/PCI vs. OMT in diabetes with CAD | ||
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease | |||
* [[CARP]] (2004): Preop coronary revascularization if stable CAD | * [[CARP]] (2004): Preop coronary revascularization if stable CAD | ||
* [[COGENT]] (2010): PPI plus clopidogrel in CAD | * [[COGENT]] (2010): PPI plus clopidogrel in CAD | ||
| Line 79: | Line 82: | ||
* [[HPS2-THRIVE]] (2014): Niacin in atherosclerotic disease | * [[HPS2-THRIVE]] (2014): Niacin in atherosclerotic disease | ||
* [[JUPITER]] (2008): Rosuvastatin for primary CV prevention | * [[JUPITER]] (2008): Rosuvastatin for primary CV prevention | ||
* [[LoDoCo]] (2013): Colchicine for stable CAD | |||
* [[MIRACL]] (2001): Atorvastatin in UA/NSTEMI | * [[MIRACL]] (2001): Atorvastatin in UA/NSTEMI | ||
* [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD | * [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD | ||
| Line 156: | Line 160: | ||
* [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS | * [[ATLAS ACS-2, TIMI 51]] (2012): Rivaroxaban after ACS | ||
* [[CAST I]] (1991): Antiarrhythmics post-MI | * [[CAST I]] (1991): Antiarrhythmics post-MI | ||
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention | |||
* [[COMMIT]] (2005): Metoprolol in acute MI | * [[COMMIT]] (2005): Metoprolol in acute MI | ||
* [[DAPT]] (2014): Aspirin/clopidogrel duration after PCI | * [[DAPT]] (2014): Aspirin/clopidogrel duration after PCI | ||
| Line 198: | Line 203: | ||
* [[AVERROES]] (2011): Apixaban vs. ASA in AF | * [[AVERROES]] (2011): Apixaban vs. ASA in AF | ||
* [[BRIDGE]] (2015): LMWH bridging for surgery in AF | * [[BRIDGE]] (2015): LMWH bridging for surgery in AF | ||
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease | |||
* [[CHARISMA]] (2006): Aspirin/clopidogrel vs. aspirin for CV prevention | |||
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | * [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | ||
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | * [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | ||
| Line 216: | Line 223: | ||
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF | * [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF | ||
* [[AVERROES]] (2011): Apixaban vs. ASA in AF | * [[AVERROES]] (2011): Apixaban vs. ASA in AF | ||
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease | |||
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | * [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | ||
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | * [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | ||
| Line 621: | Line 629: | ||
'''Coronary Artery Disease''' | '''Coronary Artery Disease''' | ||
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease | |||
* [[HOPE]] (2000): Ramipril in patients with high CV risk | * [[HOPE]] (2000): Ramipril in patients with high CV risk | ||
* [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD | * [[ORIGIN n-3 Fatty Acids]] (2012): Fish oil for high-risk CVD | ||
| Line 639: | Line 648: | ||
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF | * [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF | ||
* [[AVERROES]] (2011): Apixaban vs. ASA in AF | * [[AVERROES]] (2011): Apixaban vs. ASA in AF | ||
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease | |||
* [[CHANCE]] (2013): ASA/clopidogrel vs. ASA in TIA/stroke | |||
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | * [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | ||
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | * [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | ||
* [[ECST]] (1998): CEA in symptomatic carotid stenosis | * [[ECST]] (1998): CEA in symptomatic carotid stenosis | ||
* [[ESPRIT]] (2006): ASA+dipyridamole in secondary stroke prevention | * [[ESPRIT]] (2006): ASA+dipyridamole in secondary stroke prevention | ||
* [[FLAME]] (2011): SSRI after CVA for motor recovery | |||
* [[HOPE]] (2000): Ramipril in patients with high CV risk | * [[HOPE]] (2000): Ramipril in patients with high CV risk | ||
* [[IST]] (1997): Aspirin in acute ischemic stroke | |||
* [[MATCH]] (2004): ASA/clopidogrel vs. clopidogrel in stroke | |||
* [[MR CLEAN]] (2015): IA therapy for proximal large artery strokes | * [[MR CLEAN]] (2015): IA therapy for proximal large artery strokes | ||
* [[MR RESCUE]] (2013): Thrombectomy vs. standard care in stroke | * [[MR RESCUE]] (2013): Thrombectomy vs. standard care in stroke | ||
| Line 655: | Line 669: | ||
* [[ROCKET AF]] (2011): Rivaroxaban vs. warfarin in AF | * [[ROCKET AF]] (2011): Rivaroxaban vs. warfarin in AF | ||
* [[SPARCL]] (2006): Atorvastatin after stroke | * [[SPARCL]] (2006): Atorvastatin after stroke | ||
* [[SPS3-BP]] (2013): SBP <130 vs. SBP 130-150 after lacunar strokes | |||
'''Transient Ischemic Attack''' | '''Transient Ischemic Attack''' | ||
| Line 661: | Line 676: | ||
* [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF | * [[ARISTOTLE]] (2011): Apixaban vs. warfarin in AF | ||
* [[AVERROES]] (2011): Apixaban vs. ASA in AF | * [[AVERROES]] (2011): Apixaban vs. ASA in AF | ||
* [[CAPRIE]] (1996): Clopidogrel vs. aspirin in CV disease | |||
* [[CHANCE]] (2013): ASA/clopidogrel vs. ASA in TIA/stroke | |||
* [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | * [[CLOSURE I]] (2012): PFO closure in cryptogenic stroke | ||
* [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | * [[CREST]] (2010): Stenting vs. CEA in carotid stenosis | ||